EMA Guide To Help Regulators Assess Subgroup Analyses In Confirmatory Trials

A new final guidance by the European Medicines Agency outlines broad principles and strategies that regulatory assessors can use when investigating subgroups in confirmatory clinical trials.

Render illustration of Clinical Trial title on medical documents
EMA Guide Explains Importance Of Subgroup Analysis In Regulatory Decision-Making • Source: Shutterstock

The European Medicines Agency has issued guidance for assessors at EU regulatory agencies on how they should assess subgroup analyses in confirmatory clinical trials that are presented in marketing authorization applications.

The guideline - which may also be useful to clinical trial sponsors and regulatory assessors involved in providing scientific advice...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EMA Mapping RWD Landscape To Bridge Evidence Gap For Duchenne Drugs

 
• By 

A new EU study will assess the potential of existing Duchenne muscular dystrophy patient registries and other real-world data sources to address regulatory questions for emerging therapies.

EU Pharma Package: Keep Patients Front & Center In Defining Unmet Medical Need

 

EU trilogs on the new pharmaceutical legislation will finalize the role patients will take in influencing the development of a new definition of unmet medical need.

Defining Unmet Medical Need: EU Debate Sparks Concern Over Innovation And Access

 

Revision of the EU’s pharmaceutical legislation will include a new definition of unmet need, but getting it wrong could have unintended consequences for pricing and reimbursement.

‘Urgent Need’ To Scale Up Advice Slots Under EU HTA Regulation – EUCOPE

 

European regulators could investigate alternative ways of offering early advice to companies in relation to the Health Technology Assessment Regulation, given that official scientific advice slots are limited, a senior figure at EUCOPE says.

More from Geography

CDC Should Boost Vaccine Monitoring Transparency, Communication - National Academies Report

 
• By 

The Immunization Safety Office leveraged a “coordinated network of complementary surveillance systems” to monitor COVID-19 vaccine risks during the pandemic, but its communications faced challenges and were often intertwined with CDC efforts to promote vaccination, NASEM report finds.

Galderma’s Post Hoc Analysis Supports Nemluvio Claims But Clearer Disclosures Needed, NAD Says

 
• By 

Claims for the dermatological appearing on websites and social media were challenged by Dupixent marketer Sanofi. Galderma said it would comply with the National Advertising Division’s recommendations, a move that underscores the challenging times for DTC advertisers.

India’s R&D Financing Effort: Catalytic To De-Risking Early Innovation?

 

India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.